$XAIR News

Beyond Air Granted Nasdaq Panel Extension To Regain Compliance By July 31

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Air Subsidiary Beyond Cancer Announces Updated Follow-Up Data From Its Phase 1 UNO Trial, Notes That As Of February 2, Six Of Ten Patients Remain Alive 22-40 Months After A Single UNO Injection

Beyond Air Granted U.S. Patent Titled 'System And Method For Delivery Of Gas To A Tissue' To Treat Tumors

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

Beyond Air Awarded National Group Purchasing Agreement For Inhaled Nitric Oxide Therapy With U.S. Group Purchasing Organization

Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

Beyond Air CEO Steve Lisi Resigns, Effective March 27; Robert Goodman Appointed Successor

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Beyond Air's Subsidiary Beyond Cancer Announces Early Signs Of Clinical Activity And Safety And Tolerability Profile From Phase 1 Clinical Trial Evaluating Single Intratumoral UNO Injection Administered As Monotherapy

Beyond Air to Participate in the 38th Annual Roth Conference in March

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.

Beyond Air Says Proposed Sale Of NeuroNOS Subsidiary To XTL Biopharmaceuticals Has Been Terminated After Letter Of Intent Expired Without Definitive Agreement

Beyond Air Says Proposed Sale Of NeuroNOS Subsidiary To XTL Biopharmaceuticals Has Been Terminated After Letter Of Intent Expired Without Definitive Agreement

Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies

How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval

Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ...

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Beyond Air Comments On Independent Review Of Nitrous Oxide Respiratory Treatments